Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy

被引:1
|
作者
Wang, Weiwei [1 ]
Qu, Chaoyi [1 ]
Yan, Huanhuan [1 ]
机构
[1] Xian Peoples Hosp, Shaanxi Eye Hosp, Xian Hosp 4, Xian, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2023年 / 14卷
关键词
proliferative diabetic retinopathy; vitrectomy; conbercept; intravitreal; network meta-analysis; PARS-PLANA VITRECTOMY; LINEAR MIXED MODELS; SYSTEMATIC REVIEWS; HEALTH-CARE; INCONSISTENCY; BEVACIZUMAB; PRETREATMENT; RANIBIZUMAB;
D O I
10.3389/fendo.2023.1098165
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PurposeIntravitreal Conbercept (IVC) has been shown to be effective in treating proliferative diabetic retinopathy (PDR) as an adjuvant in pars plana vitrectomy (PPV); however, the best timing of IVC injection remains unknown. This network meta-analysis (NMA) sought to ascertain the comparative efficacy of different timings of IVC injection as an adjuvant to PPV on PDR. MethodsA comprehensive literature search was conducted in PubMed, EMBASE, and the Cochrane Library to identify relevant studies published before August 11, 2022. According to the mean time of IVC injection before PPV, the strategy was defined as very long interval if it was > 7 days but <= 9 days, long interval if it was > 5 days but <= 7 days, mid interval if it was > 3 days but <= 5 days, and short interval if it was <= 3 days, respectively. The strategy was defined as perioperative IVC if IVC was injected both before and at the end of PPV, and the strategy was intraoperative IVC if injected immediately at the end of PPV. The mean difference (MD) and odds ratio (OR) with corresponding 95% confidence interval (CI) for continuous and binary variables, respectively, were computed through network meta-analysis using Stata 14.0 MP. ResultsEighteen studies involving 1149 patients were included. There was no statistical difference between intraoperative IVC and control in treating PDR. Except for a very long interval, preoperative IVC significantly shortened operation time, and reduced intraoperative bleeding and iatrogenic retinal breaks. Long and short intervals reduced endodiathermy application, and mid and short intervals reduced postoperative vitreous hemorrhage. Moreover, long and mid intervals improved BCVA and central macular thickness. However, very long interval was associated with an increased risk of postoperative vitreous hemorrhage (RR: 3.27, 95%CI: 1.84 to 5.83). Moreover, mid interval was better than intraoperative IVC in shortening operation time (MD: -19.74, 95%CI: -33.31 to -6.17). ConclusionsThere are no discernible effects of intraoperative IVC on PDR, but preoperative IVC, except for very long interval, is an effective adjuvant to PPV for treating PDR.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Appropriate timing schedule for intravitreal anti-VEGF injection as adjuvant therapy before pars-plana vitrectomy in proliferative diabetic retinopathy, a meta analysis
    Bagheri, Masood
    Salari, Nader
    Aghaei, Naser
    Yarmohammadi, Maryam
    EXPERT REVIEW OF OPHTHALMOLOGY, 2023, 18 (03) : 205 - 222
  • [22] Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy
    Lu, Qianyi
    Lu, Li
    Chen, Bin
    Chen, Wei
    Lu, PeiRong
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2019, 54 (03): : 291 - 296
  • [23] Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy
    K Ishikawa
    S Honda
    Y Tsukahara
    A Negi
    Eye, 2009, 23 : 108 - 111
  • [24] Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy
    Ishikawa, K.
    Honda, S.
    Tsukahara, Y.
    Negi, A.
    EYE, 2009, 23 (01) : 108 - 111
  • [25] The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study
    Jiang, Tingting
    Gu, Junxiang
    Zhang, Peijun
    Chen, Wenwen
    Chang, Qing
    BMC OPHTHALMOLOGY, 2020, 20 (01)
  • [26] The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study
    Tingting Jiang
    Junxiang Gu
    Peijun Zhang
    Wenwen Chen
    Qing Chang
    BMC Ophthalmology, 20
  • [27] Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy
    Hu, Liting
    Chen, Qiulu
    Du, Zhaodong
    Wang, Wenying
    Zhao, Guiqiu
    INTERNATIONAL OPHTHALMOLOGY, 2021, 41 (05) : 1635 - 1642
  • [28] Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy
    Liting Hu
    Qiulu Chen
    Zhaodong Du
    Wenying Wang
    Guiqiu Zhao
    International Ophthalmology, 2021, 41 : 1635 - 1642
  • [29] The effect and safety of intravitreal ranibizumab combined with vitrectomy for proliferative diabetic retinopathy
    Rong, Hua
    Xu, Yueli
    Zhang, Meiping
    Cai, Minyun
    Cui, Hongping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (04): : 7163 - 7167
  • [30] Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy
    Hernandez-Da Mota, Sergio E.
    Nunez-Solorio, Silvia M.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2010, 20 (06) : 1047 - 1052